← Evidence map

ArticleThe oncologist2026

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the "Rebiopsy on Osi" study).

Eleonora Gariazzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the "Rebiopsy on Osi" study). | OpenQuestion